Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · Real-Time Price · USD
1.830
+0.030 (1.67%)
Sep 6, 2024, 4:00 PM EDT - Market closed
Company Description
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | David Lennon |
Contact Details
Address: 17383 Sunset Boulevard, Suite A250 Pacific Palisades, California 90272 United States | |
| Phone | 424 744 8055 |
| Website | aadibio.com |
Stock Details
| Ticker Symbol | AADI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422142 |
| CUSIP Number | 00032Q104 |
| ISIN Number | US00032Q1040 |
| Employer ID | 61-1547850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David J. Lennon Ph.D. | President, Chief Executive Officer and Director |
| Dr. Neil P. Desai Ph.D. | Founder and Executive Chairman |
| Scott M. Giacobello CPA | Chief Financial Officer, Treasurer, Investor Relations and Corporate Communications |
| Dr. Loretta M. Itri F.A.C.P., M.D. | Chief Medical Officer |
| Stephen M. Rodin J.D. | Senior Vice President of Legal and General Counsel |
| Raymond G. Steitz | Senior Vice President of Human Resources and Chief Human Resources Officer |
| Bryan Ball | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 3, 2024 | 144 | Filing |
| Aug 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 22, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Jun 12, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 144 | Filing |
| May 8, 2024 | 10-Q | Quarterly Report |